ALK and lung adenocarcinoma: According to research, EVs secreted from an anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor (TKI)-resistant subclone of ALK-translocated lung adenocarcinoma cell lines can cause drug resistance in sensitive subclones [213].